Short interest for Intra-Cellular Therapies gives investors a sense of the degree to which investors are betting on the decline of Intra-Cellular Therapies's stock. Short interest data is updated every two weeks.

Intra-Cellular Therapies Stock (NASDAQ:ITCI), Short Interest Report

Intra-Cellular Therapies

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Earnings

News

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

ITCI

OTRK

With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday

Small Cap

Intraday Update

Movers

ACDC

ADXN

BACK

BENF

BNED

BSGM

CGEM

CLDI

CSLR

CTNM

DFLI

DYNT

ERIC

JAGX

KAVL

MCBC

MNSO

PACB

PALI

PRFX

PRSO

PRZO

RNAC

RVYL

SKIL

SMXT

SPRC

SXTC

SYTA

TAOP

WISA

WFTC

Shares of  Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.

Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Lab.julia koblitz

Biotech

Health Care

Previews

General

Unlock new hope for major depressive disorder with Lumateperone 42 mg. Results from Intra-Cellular&#39;s Study 501, show significant symptom relief as adjunctive therapy to antidepressants.

Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies Inc

<p>Throughout the last three months, 18 analysts have evaluated Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $91.94, a high estimate of $120.00, and a low estimate of $77.00. Marking an increase of 11.44%, the current average surpasses the previous average price target of $82.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715198429_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Intra-Cellular Therapies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>-</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>-</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$120.00</td>
<td>-</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$96.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Corinne Jenkins</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$77.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Joseph Thome</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$86.00</td>
<td>-</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$101.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$86.00</td>
<td>-</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intra-Cellular Therapies. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Intra-Cellular Therapies's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Intra-Cellular Therapies's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Intra-Cellular Therapies analyst ratings.</strong></a></p>
<h2>Delving into Intra-Cellular Therapies's Background</h2>
<p>Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.</p>
<h3>Intra-Cellular Therapies: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Intra-Cellular Therapies's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>50.41%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Intra-Cellular Therapies's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-21.73%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Intra-Cellular Therapies's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-4.79%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Intra-Cellular Therapies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-3.95%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Intra-Cellular Therapies's debt-to-equity ratio is below the industry average at <strong>0.03</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Analyst Ratings For Intra-Cellular Therapies

<p>Needham  analyst Ami Fadia   reiterates Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Buy and maintains $90 price target.</p>


Price Target

Reiteration

Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $90 Price Target

Guidance

Intra-cellular Therapies Reiterates Full Year 2024 Caplyta Net Product Sales Guidance Of $645M-$675M

Earnings Beats

Intra-Cellular Therapies Q1 2024 GAAP EPS $(0.16) Beats $(0.32) Estimate, Sales $144.866M Beat $141.381M Estimate

<p>Cantor Fitzgerald  analyst Charles Duncan   reiterates Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Overweight and maintains $120 price target.</p>


Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $120 Price Target

<p>Canaccord Genuity  analyst Sumant Kulkarni   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Buy and raises the price target from $100 to $107.</p>


Canaccord Genuity Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $107

<p>Needham  analyst Ami Fadia   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Buy and raises the price target from $82 to $90.</p>


Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $90

<p>Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) in the last three months.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average target of $88.86, a high estimate of $103.00, and a low estimate of $77.00. Marking an increase of 10.55%, the current average surpasses the previous average price target of $80.38. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713790837_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Intra-Cellular Therapies among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$96.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Corinne Jenkins</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$77.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Joseph Thome</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$86.00</td>
<td>-</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$101.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$86.00</td>
<td>-</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$86.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Intra-Cellular Therapies. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Intra-Cellular Therapies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Intra-Cellular Therapies's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Intra-Cellular Therapies analyst ratings.</strong></a></p>
<h2>About Intra-Cellular Therapies</h2>
<p>Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.</p>
<h3>Intra-Cellular Therapies's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Intra-Cellular Therapies showcased positive performance, achieving a revenue growth rate of <strong>50.41%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-21.73%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Intra-Cellular Therapies's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-4.79%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Intra-Cellular Therapies's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-3.95%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Intra-Cellular Therapies's debt-to-equity ratio is below the industry average at <strong>0.03</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts

<p>Mizuho  analyst Graig Suvannavejh   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Buy and raises the price target from $82 to $96.</p>


Mizuho Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $96

<p><strong>Intra-Cellular Therapies's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NYSE">ITCI</a>) short percent of float has risen 4.8% since its last report. The company recently reported that it has <strong>3.47 million shares sold short</strong>, which is 4.15% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 5.55 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Intra-Cellular Therapies Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713542428_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Intra-Cellular Therapies has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Intra-Cellular Therapies's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Intra-Cellular Therapies's peer group average for short interest as a percentage of float is 3.98%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

How Is The Market Feeling About Intra-Cellular Therapies?

WIIM

Intra-Cellular Therapies shares are trading lower after the company priced a $500 million offering.

<p>All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $500.0 million before deducting underwriting discounts and commissions and offering expenses.</p>


Reported Earlier, Intra-Cellular Therapies Prices Public Offering Of 6,849,316 Common Shares At $73/Share

<p>Goldman Sachs  analyst Corinne Jenkins   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Neutral and raises the price target from $67 to $77.</p>


Goldman Sachs Maintains Neutral on Intra-Cellular Therapies, Raises Price Target to $77

<p>B of A Securities  analyst Jason Gerberry   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Buy and raises the price target from $82 to $91.</p>


B of A Securities Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $91

<p>Baird  analyst Joel Beatty   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Outperform and raises the price target from $83 to $103.</p>


Baird Maintains Outperform on Intra-Cellular Therapies, Raises Price Target to $103

<p>TD Cowen  analyst Joseph Thome   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Buy and raises the price target from $80 to $90.</p>


TD Cowen Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $90

<p>With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:</p>
<p>Wall Street expects <strong> Abbott Laboratories</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abt#NYSE">ABT</a>) to report quarterly earnings at 95 cents per share on revenue of $9.88 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Abbott shares gained 1% to $110.30 in after-hours trading.</p>
<p><strong>Intra-Cellular Therapies, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/itci#NASDAQ">ITCI</a>) disclosed a $500 million proposed public offering of common stock. Intra-Cellular Therapies shares fell 1.3% to $78.80 in the after-hours trading session.</p>
<p>Analysts are expecting <strong> U.S. Bancorp </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usb#NYSE">USB</a>) to post quarterly earnings at 88 cents per share on revenue of $6.72 billion. The company will release earnings before the markets open. U.S. Bancorp shares fell 0.6% to $40.75 in after-hours trading.</p>
<p><em>Check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> </em></p>
<p><strong>Ontrak, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otrk#NASDAQ">OTRK</a>) reported worse-than-expected fourth-quarter financial results. The company posted adjusted loss of 27 cents per share, compared to market expectations for a loss of 21 cents per share.&nbsp;The company&#39;s quarterly sales came in at $3.539 million, missing estimates of $4.037 million.&nbsp;Ontrak shares fell 14.2% to $0.3949 in the after-hours trading session.</p>
<p>Analysts expect <strong> The Travelers Companies, Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/trv#NYSE">TRV</a>) to post quarterly earnings at $4.90 per share on revenue of $10.51 billion before the opening bell. Travelers shares gained 0.8% to $224.98 in after-hours trading.</p>
<p>Check This Out: <a href="https://www.benzinga.com/news/24/04/38268727/top-4-tech-stocks-you-may-want-to-dump-in-april"><em> Top 4 Tech Stocks You May Want To Dump In April </em></a></p>


<p>Intra-Cellular Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) ("Intra-Cellular Therapies"), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering will be sold by Intra-Cellular Therapies.<br /><br />&nbsp;</p>
<p>J.P. Morgan, Leerink Partners, BofA Securities, Morgan Stanley and RBC Capital Markets are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p>


Offerings

Intra-Cellular Therapies Announces $500M Proposed Public Offering Of Common Stock

Intra-Cellular Therapies Inc Files For Mixed Shelf Offering, Size Not Disclosed

Intra-Cellular Therapies beats Q1 estimates

Analyst Ami Fadia of Needham maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), retaining the price target of $90.00. Am...

Buy Rating Affirmed: Intra-Cellular Therapies Exceeds Q1 Expectations with Caplyta Sales Surge

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Intra-Cellular Therapies</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/itci-stock-quote/"><strong>ITCI</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Intra-Cellular Therapies reported earnings per share of -16 cents. This was above the analyst estimate for EPS of -33 cents.</li><li>The company reported revenue of $144.87 million.</li><li>This was 2.81% better than the analyst estimate for revenue of $140.91 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/itci-stock-earnings-intra-cellular-therapies-for-q1-of-2024/">ITCI Stock Earnings: Intra-Cellular Therapies Beats EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ITCI Stock Earnings: Intra-Cellular Therapies Beats EPS, Beats Revenue for Q1 2024

Intra-Cellular Therapies, Inc. (ITCI) Q1 2024 Earnings Call Transcript

Intra-Cellular Therapies (ITCI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Corinne Joh...

Intra-Cellular Therapies: A Hold Rating Amid Anticipation of Critical Phase 3 Data and Diverse Clinical Pipeline

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), with ...

RBC Capital Remains a Buy on Intra-Cellular Therapies (ITCI)

Sumant Kulkarni, an analyst from Canaccord Genuity, maintained the Buy rating on Intra-Cellular Therapies (ITCI – Research Report). The associated ...

Intra-Cellular Therapies: A Strong Buy on Robust Financials and Promising Caplyta Prospects

Intra-Cellular Therapies (ITCI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 7. Analyst Joel Bea...

Intra-Cellular Therapies: A Buy Rating on Solid Financials and Promising Drug Development

Marc Goodman, an analyst from Leerink Partners, reiterated the Buy rating on Intra-Cellular Therapies (ITCI – Research Report). The associated pric...

Buy Rating Affirmed on Intra-Cellular Therapies Amid Strong Sales and Promising Clinical Trials

In a report released on May 8, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Intra-Cellular Therapies (ITCI – Research Report...

Maintained Buy Rating on ITCI Shares Amidst Strong Caplyta Revenue and Positive MDD Study Outlook

Press Releases

Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

Management

Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

Intra-Cellular Therapies Prices Public Offering of Common Stock

Financing

Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast

Intra-Cellular Therapies Reports First Quarter 2024 Financial Results

Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Indivior

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly and Co

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Intra-Cellular Therapies Stock (NASDAQ:ITCI), Short Interest Report

People Also Watch